Aclarion Partners with PRIA Healthcare to Accelerate Nociscan Reimbursement, US Commercial Adoption
Summary
Aclarion has partnered with PRIA Healthcare to launch a Market Access Program for its AI-powered Nociscan platform, aiming to accelerate reimbursement and commercial adoption in the U.S. This is a critical step for the micro-cap company, especially following its recent rejection of an acquisition offer and strong Q1 growth in Nociscan scan volumes. PRIA Healthcare's expertise in payer engagement and prior authorization is crucial for overcoming market access barriers and driving revenue for Aclarion's core product.
At the time of this announcement, ACON was trading at $3.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $2.34 to $12.03. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.